October 24, 2017
Sonoran Biosciences has filed a new provisional patent application on improved formulation and stability of SB Gel platform
Sonoran Biosciences, Inc., a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the treatment and prevention of serious biofilm infections, today announced the filing of a provisional patent application in the United States related to its platform technology SB Gel, which is an important step in providing intellectual and commercial protection for its platform technology and its lead formulation, SBG002.
Sonoran is developing sustained release pharmaceutical formulations using a novel and proprietary drug delivery carrier, SB Gel. SB Gel is an aqueous solution of a temperature-responsive polymer which forms a hydrogel for the sustained release of drugs at body temperature. The newly filed provisional patent application includes claims related to the composition and methods of use of the SB Gel polymer solutions, including their preparation with a variety of drugs.
About Sonoran Biosciences, Inc.
Sonoran Biosciences is a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the treatment and prevention of serious biofilm infections, especially those that occur after surgery. The company’s lead product SBG002 is an injectable sustained-release gel containing tobramycin and vancomycin designed for direct application in surgical sites. SBG002 has the potential to become a first-in-class product for treatment and prevention of a wide variety of serious infections, and is being developed toward a lead indication in one-stage treatment of periprosthetic joint infection (PJI), the most common and costly reason for failed arthroplasty.